GlassScriptPhysician profile
Tassew Tesfaye
NPI 1710974696
$766.04
in general payments reported to CMS, 2019-2025
16 companies · $91.77 in 2025
The $91.77 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2020: $282 · 2021: $93.72 · 2022: $13.86 · 2023: $135 · 2024: $29.95 · 2025: $91.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $157.35 | 2019-2020 | |
| Amgen INC. | $138.77 | 2020-2023 | Otezla, Repatha |
| Redhill Biopharma INC. | $80.68 | 2020-2021 | |
| Amarin Pharma, INC. | $78.60 | 2020 | |
| Novo Nordisk INC | $60.52 | 2021-2024 | Rybelsus, Ozempic |
| Abbott Laboratories | $56.37 | 2023 | Freestyle Libre 2 |
| Lilly USA, LLC | $37.87 | 2021-2024 | Mounjaro |
| Boston Scientific Corporation | $22.18 | 2025 | General - Pain Management |
| E.R. Squibb & Sons, L.L.C. | $20.11 | 2025 | Cobenfy |
| Glaxosmithkline, LLC. | $19.65 | 2025 | Shingrix |
| Horizon Therapeutics Plc | $17.69 | 2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $17.05 | 2023 | Breztri |
| Phadia US INC. | $15.51 | 2021 | |
| Gilead Sciences, INC. | $15.51 | 2025 | |
| Exact Sciences Corporation | $14.32 | 2025 | Cologuard Collection Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tassew Tesfaye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.